Track 3 - January 24 11.15 A.M.-11.45 A.M.
Phenoconversion is a phenomenon by which an individual’s genotype-predicted phenotype is transformed into another by factors such as drug interactions or diseases. This session will cover complexities of genotype result interpretation in clinical practice and clinical trials since phenoconversion makes challenging such translation of information into clinically actionable recommendations.
Session Chair Profile
Ph.D., Chief Scientific Officer, Tabula Rasa HealthCare
Biography
Jacques Turgeon directs scientific advances at TRHC that leads to the development of new Risk Stratification Strategies and Clinical Decision Support Systems. He is recognized internationally for his excellence in research and pharmacy education. He has received >$70 million in research awards and authored >130 peer-reviewed articles. He is renowned for his expertise on the cytochrome P450 system, drug-induced Long QT Syndrome and pharmacogenetics. Dr. Turgeon has held numerous leadership roles including serving as Dean of the School of Pharmacy and Vice-Rector of Research at the University of Montreal; Director of the University of Montreal Hospital Research Centre; Chief Executive Officer of the University of Montreal Hospital and Associate Dean, College of Pharmacy, University of Florida. Dr. Turgeon is Professor Emeritus from University of Montreal, a fellow of the Canadian Academy of Health Sciences and a fellow of the Académie Nationale de Médecine in France.
Speaker Profile
BPharm, Ph.D., Chief Operating Officer, THRC Precision Pharmacotherapy Research & Development Institute; Adjunct Professor, University of Montreal
Biography
Dr Michaud is the Chief Operating Officer of the Tabula Rasa Healthcare Scientific Precision Pharmacotherapy Research & Development Institute in Orlando. The institute aims at developing advanced clinical decision support systems to optimize medication safety. She is an adjunct professor, Faculty of pharmacy, Université de Montréal and has directed a pharmacokinetic and bioanalytic core facility at the CRCHUM. Her research investigates the contribution of CYP450 drug-metabolizing enzymes in drug disposition, with a special attention to the role of disease states (focusing on type 2 diabetes), the role of pharmacogenomics and drug-drug interactions while attempting to better understand and predict variation in drug responses. She has earned more than $22 million in research awards, published more than 35 peer-reviewed journal articles and mentored graduate students and PharmD residents. She completed fellowships at Indiana University and McGill University and earned her Ph.D. and M.Sc. degrees from the Université de Montréal.
Speaker Profile
Ph.D., Professor of Medicine, Indiana University School of Medicine
Biography
Todd Skaar did his graduate work in nutrition at the University of Wisconsin, lactation physiology at the Penn State University, and a postdoc in breast cancer drug resistance at the Lombardi Cancer Center at Georgetown University. Since joining the Division of Clinical Pharmacology at the Indiana University School of Medicine, his research has focused on the discovery and implementation of genomic predictors of drug response. More specifically, his studies are focused on identifying and functionally testing genetic variants in the drug metabolism genes that are associated with clinical drug efficacy and toxicity. They also include studies to identify miRNAs that contribute to the drug-induced and developmental changes in hepatic drug metabolism. He co-leads multiple pharmacogenomics implementation clinical trials focused on identifying and overcoming the barriers to using pharmacogenomics to guide drug therapies. He is also a co-leader of the Cancer Prevention & Control Program of the Indiana University Cancer Center.
